Jason T. Gammack

Join us in San Diego for #RNALeaders Sept 4, 5.  We are updating partners on our latest IV-formulated RNA program data. BIORCHESTRA Co., Ltd.'s #RNAi update covers: ✨ In-vivo progress on our neurodegenerative diseases franchise and proprietary IV-formulated RNAi research in #Alzheimer's and #Parkinson's ✨ Status of our #ALS program FDA IND pathway  ✨ Licensing negotiations for #MAPT, #SNCA, #INHBE/ #MAFLD, and #Glaucoma ✨ Our bridge round syndicate and #NYSE pathway To those requesting one-on-ones though LinkedIn, please reach us at [email protected] Novo Nordisk, SV Health Investors, PJT Partners, Perella Weinberg, William Blair Investment Banking, Jefferies, Leerink Partners, Nomura Securities International, Inc., Cain Brothers, UBS, Oppenheimer & Co. Inc., Wells Fargo Corporate & Investment Banking, Guggenheim Partners, Outcome Capital, Eric J. Dimise, PhD, Michael Bardi, Michael Zhang, Veet Misra, Cantor Fitzgerald, Noël Brown, Samuel Siu, CPA, RBC Capital Markets, John C. Reed, Novo Holdings, Lilly Asia Ventures 礼来亚洲基金, Sumitomo Mitsui Banking Corporation – SMBC Group, #pfizercolleague, Centerview Partners, Morgan Stanley Investment Management, Bank of America, Mallinckrodt Pharmaceuticals, Grünenthal Group, Evercore, New York Stock Exchange https://lnkd.in/gaWRkNDU The Janssen Pharmaceutical Companies of Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., ONO PHARMA USA, ONO PHARMACEUTICAL CO., LTD., Sanofi, Novartis Gene Therapies

24

Very useful assay developed by Celtarys Research for those working on #GPCR , replace radioactivity with #fluorescence - #medchem #medicinalchemistry #greenchemistry

7

Learn more out AAV Process Development and Optimization using cloud-connected bioreactors. Come visit the Culture Biosciences Team at ASGCT. #processdevelopment #processoptimization #cloudconnectivity #aav #bioprocess

15

1 Comment

Also in This Issue: The single-drop pan-diagnostic is back (for real this time) Early Cancer Detection tests - ready for prime time? Adding liquid bx to standard tumor staging acronym Bird flu update #sensitiveandspecific #diagnostics #genetics #genomics #personalizedmedicine #infraredspectroscopy #proteomics #biomarkers #diseasedetection #birdflu #H5N1 #MCED #MCEDtest #earlydetection #liquidbiopsy #olympics #wastewatersurveillance

18

Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs - BioSpace Nucleus RadioPharma’s two sites are meant to help address the industry’s lack of manufacturing and development capabilities, as well as geographic limitations associated with the short half-life of many radioactive components. AstraZeneca-backed Nucleus RadioPharma on Monday unveiled plans for two new manufacturing facilities—one in #Arizona and another in #Pennsylvania—to address critical bottlenecks in the radiopharmaceuticals space. Together, the Arizona and Pennsylvania sites will expand Nucleus’ U.S. footprint by more than 100,000 square feet and will add 100 new jobs—50 at each location—helping to establish the respective regions as healthcare hubs, according to the company. Construction on both plants is expected to be completed by the end of 2026. “To reach their full potential as treatments for millions of patients with limited options, theranostic radiopharmaceuticals must be available close to those who need them,” Nucleus CEO Charles Conroy, RPh, MBA said in a statement, noting that the two new sites will “significantly improve patient access” to radiopharmaceuticals and “expedite clinical trials.” Conroy expects the Arizona and Pennsylvania plants to cut “time-to-market for new therapies by up to 30%.” According to Nucleus, these new manufacturing facilities will be “first-of-a-kind” bringing together research, development and commercial production processes “under one roof.” This level of integration will give Nucleus’ partners “massive time and scale advantage,” the company contends, while providing a solution to the current supply chain constraints nationwide. https://lnkd.in/eTuF8btb

32

High Cost of Laboratory Space Preventing Expansion? At Colorado Health & Tech Centers (CHTC), we offer solutions. CHTC is prepared to support the growing life sciences and biotech ecosystem with partially equipped laboratories to streamline lab setup and flexible terms. Don’t let the high cost of setting up a lab hinder your innovation. Join the myriad entrepreneurs who have experienced the benefits of competitively priced, world-class laboratory and office space. https://coloradohtc.com/ #COHubforHealthImpact, #COLeadsLifeSciences, #Denverrealestate, #biotechnology, #Pharmaceutical, #biotech, #pharma, #innovation, #tech, #Technology, #CBSA, #CoBioscience, #cro , #cdmo , #laboratory,  #relocationspecialist, #Medicaldevice, #entrepreneurship, #startups, #future, #India, #USA, #UK, #UAE, #biomanufacturing, #Quantum, #Quantumtechnology

38

1 Comment

🚀 Big News in Biopharma! 🚀 Profluent is making waves at the intersection of biotech and AI. Their innovative approach promises to revolutionize gene editing, and they're doing it with a bold move: open-sourcing their work! 🌐🔬 Introducing OpenCRISPR 🧬 Profluent's OpenCRISPR initiative is set to provide customizable gene-editing proteins designed entirely by AI. Imagine AI-generated CRISPR-like proteins that have never been seen before, capable of editing the human genome with unparalleled precision. 🔍 Highlights: AI-Powered: Trained on vast databases of protein sequences, Profluent's AI can generate hundreds of thousands of CRISPR-like proteins. OpenCRISPR-1: Their top-performing AI-created gene editor boasts 400+ mutations compared to CRISPR-Cas9, reducing off-target editing by 95% and keeping unwanted genetic changes below 1%. Why This Matters Attempting to edit human DNA with AI-designed systems is nothing short of a scientific moonshot. Profluent's success points to a future where AI can design bespoke cures for diseases, democratizing gene editing. 🔬 Real-World Impact: While AI-designed drugs have been in clinical testing for years, CRISPR tech just got its FDA green light last year with Casgevy for sickle cell disease and beta thalassemia. These treatments show the incredible potential of gene editing to transform lives. Open Collaboration Profluent invites researchers to test and provide feedback on OpenCRISPR-1. Their goal is to partner with top research institutions and drug developers to expedite the development of new genetic therapies, ensuring safe and ethical practices. Recent Milestones $35M Funding: Backed by Spark Capital, Insight Partners, Air Street Capital, and top angel investors from OpenAI, Salesforce, and Google. Join the Revolution This is a watershed moment in gene editing. Profluent is not just pushing the boundaries of what's possible; they’re opening the doors for global collaboration. Let's build the next generation of genetic medicines together! 👉 Read more and get involved: https://lnkd.in/gN9p-H6j #GeneEditing #CRISPR #AI #Biotech #OpenSource #Innovation #Profluent #HealthcareRevolution

18

7+ years ago, the first Hyperion Imaging Mass Cytometer launched, making high content proteomics tissue imaging a possibility for the masses (no pun intended). Now, with Hyperion XTi Imaging Mass Cytometer, we are about to take those capabilities to the next level! Please join David's (David King) talk to see how spatial biology, paired with the massive amounts of data you already have, can give you the ACTIONABLE insights you need to make a successful therapeutic! #spatialbiology #imagingmasscytometry #immunofluorescence #immunohistochemistry #mrna #protein #cytof #flowcytometry #masscytometry #celltherapy #immunooncology #immunotherapy #oncology #neuroscience #neurology #cardiology #molecularimaging

17

xcellbio Biosciences Inc. (Xcellbio) announced the advancement of its collaboration with Labcorp through the installation of a new AVATAR™ Foundry system at Labcorp's Ann Arbor, Michigan site. This beta access program installation enables scientists to extend potency benefits from small-scale to large-scale automated cell therapy manufacturing workflows. Labcorp, a longstanding collaborator of Xcellbio, joins the early members of the AVATAR Foundry beta access program. Xcellbio's AVATAR incubator system, including the AVATAR Odyssey and the latest AVATAR Foundry system, delivers innovative capabilities for enhancing the potency of cell and gene therapies. These advancements are crucial for optimizing cell therapies targeting solid tumors, particularly in challenging tumor microenvironments. #potency #celltherapy #advancedtherapies #regenerativemedicine #collaboration #betasite #expansion #biotech #biotechnology #lifescience #lifesciences #persistence #tumormicroenvironment #TME #genetherapy #enhancedworkflows #automation #solidtumors #oncology #cancer

68

2 Comments

High Cost of Laboratory Space Preventing Expansion? At Colorado Health & Tech Centers (CHTC), we offer solutions. With partially equipped laboratories to streamline lab set up and flexible terms, CHTC is prepared to support the growing life sciences and biotech ecosystem. Don’t let the high cost of setting up a lab hinder your innovation. Join the myriad of entrepreneurs who have experienced the benefits of competitively priced, world-class laboratory and office space. https://coloradohtc.com/ #Denverrealestate, #biotechnology, #Pharmaceutical, #biotech, #pharma, #innovation, #tech, #Technology, #CBSA, #CoBioscience, #cro , #cdmo , #contractmanufacturing, #laboratory,  #relocationspecialist, #Medicaldevice, #entrepreneurship, #startups

18

1 Comment

CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia Highlights • CD37 is expressed on AML blasts • CD37 expression correlates with ELN 2017 risk stratification • CD37CAR T cells are efficient against AML in vitro and in vivo • CD37CAR T cells do not deplete myeloid progenitors Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard induction therapy, and new forms of therapy are urgently needed. Chimeric antigen receptor (CAR) T therapy has so far not been successful in AML due to lack of efficacy and safety. Indeed, the most attractive antigen targets are stem cell markers such as CD33 or CD123. We demonstrate that CD37, a mature B cell marker, is expressed in AML samples, and its presence correlates with the European LeukemiaNet (ELN) 2017 risk stratification. We repurpose the anti-lymphoma CD37CAR for the treatment of AML and show that CD37CAR T cells specifically kill AML cells, secrete proinflammatory cytokines, and control cancer progression in vivo. Importantly, CD37CAR T cells display no toxicity toward hematopoietic stem cells. Thus, CD37 is a promising and safe CAR T cell AML target. https://lnkd.in/esqup3tf

125

2 Comments

RNA Breakthrough in ALS: Restoring PGC1a & STMN2 for Neuroprotection BIORCHESTRA Co., Ltd.'s ALS neurotherapeutic program enables efficient and effective targeted RNAi to the CNS. Our industry-first, IV-formulated approach achieves unmatched uptake in #astrocytes, #microglia, and #neurons, pushing the boundaries of ALS treatment. Targeting the Core of ALS Pathology Our lead program addresses ALS at its roots by restoring the function of #PGC1a and #STMN2, crucial mitochondrial dynamics and axonal health regulators. These pathways are essential for combating neurodegeneration, reducing inflammation, and preserving motor and cognitive function. Latest In Vivo Evidence --PGC1a: In animal models, enhancing PGC1a expression improves mitochondrial function, which is vital for energy production and neuron survival. Studies show that boosting PGC1a mitigates mitochondrial dysfunction in ALS, leading to better motor neuron health and delayed disease progression. --STMN2: This protein is critical for axonal stability and neuromuscular junctions (NMJs). ALS News Today highlights that STMN2 loss results in disorganized NMJs and impaired motor function, mirroring ALS progression. Our RNAi approach targets an upstream microRNA to restore PGC1a and STMN2 expression, with in vivo data confirming successful restoration. Other studies show the protection of neurons, promotion of axonal repair, and improved motor neuron survival, even in TDP-43 pathology. Potential to Halt ALS Progression: Our latest data lay the groundwork for ongoing study, supporting the therapeutic potential of targeting PGC1a and STMN2 to enhance neuroprotection and slow ALS. With a profound commitment to ALS patients like Steve Gleason, we are ambitiously accelerating this lead program to bring a solution to those battling ALS. May Guo, Sebastian Guth, Bill Sessa, David Morrissey, Congsheng Cheng, John Griffin, Ted W. Love, MD. NBC Special on NFL Player Steve Gleason's Journey with ALS: https://lnkd.in/gPkNQsn3

13

Would you be surprised to learn that in spite of Mass Spec's designation as the "Gold Standard" for chemical analysis that most systems are designed to throw away 99% of the available signal when analyzing complex samples? We've come up with a way to capture all of that lost signal, boosting sensitivity up to 100x. Oh, and this approach also does MS/MS analysis up to 10x faster than other systems. Want to learn more about the future of high performance mass spec? Click below to see our new press release.

45

2 Comments

EXO-Harvest to launch breakthrough scalable fixed-bed bioreactor platform for MSC and EVs manufacturing - https://lnkd.in/gc5cKeQ6 EXO-Harvest, an affiliate of convEyXO, is thrilled to announce the successful launch of its cutting-edge multi-scale bioreactor platform for adherent cells and extracellular vesicles (EVs) production, in partnership with IPRATECH. The platform is now fully operational, marking a significant milestone in joint efforts to advance biotechnological solutions through engineering excellence. EXO-Harvest’s launch of the breakthrough multi-scale bioreactor platform will help overcome the challenges of MSC and EV manufacturing, to make therapies “triple A” from day one —Available, Accessible, and Affordable. EXO-Harvest created 2 versions: a small-scale multi-bioreactor for process development and a mid/large scale bioreactor for clinical lot production. The small scale multi-parallel screening platform offers a cost-efficient way for process development of cells and EVs production from small to mid-scales for full industrialization. The automated and integrated system enables rapid optimization of all critical parameters such as culture media and refreshment strategies, fixed beds and their geometries, fluidics and kinetics, among others. ConvEyXO successfully integrated this innovative multi-scale bioreactor platform, utilizing EXO-Harvest as an enabler to progress, in a cost-efficient way, towards clinical product development and industrialization. With EXO-Harvest’s multi-scale bioreactor platform as an enabler, convEyXO advances its anti inflamm-aging therapeutic product development reducing the cost and time, while optimizing the EV production of their WJ-iMSC’s and achieving a 1010 EV/cm2 of adherence with the custom fixed bed bioreactor. Based on convEyXO WJ-iMSC cell line and EXO-Harvest manufacturing capabilities, convEyXO can consider producing batches with unprecedented homogeneity and affordability. Read more at: https://lnkd.in/gc5cKeQ6 #exosomes #extracellularvesicles #advancedtherapies #bioreactor Borg Hemelaer Frédéric Tonglet

24

2 Comments

🔬Scalable and viable CGT products gain a competitive edge With Carl Schoellhammer Principal & Advanced Therapies Practice Lead at DeciBio, Jason C. Foster discusses why cell viability and optimizing biological processes through automation is just one side of the equation. Ensuring that these therapies can also be commercially scaled efficiently is equally important. By addressing these key aspects of manufacturing and viability early, we can accelerate the development of life-saving therapies and ensure they reach the patients who need them most. Listen to full conversation on the Ori Spotlight Podcast: 🎧 Spotify: https://lnkd.in/edeXBaqn 📺 YT: https://lnkd.in/evZvW4b8 #AutomateBetterBiology #CellTherapy #GeneTherapy #PatientAccess

49

1 Comment

Immunologix Laboratories is excited to provide off-the-shelf MSD V-Plex Proinflammatory Panel 1 and Chemokine Panel 1 supported by a comprehensive analytical performance package designed to meet the needs of varied contexts of use. These panels measure 20 critical #biomarkers in human plasma and serum. In addition to delivering impeccable precision, our comprehensive approach aligns #biomarkeranalysis with specific context of use by fully evaluating how these methods perform with endogenous molecules in real samples. This brings a level of confidence to your analysis that cannot be achieved using surrogate molecules and matrix as typically quoted in manufacturer claims. https://lnkd.in/gSb3bwG

9

Join BIORCHESTRA Co., Ltd. on-site for the Fierce Biotech Summit in Boston from September 30 to October 1, where we will share detailed updates on our IV- and SC-formulated RNAi therapeutics, including: 🔬 IV-Formulated RNAi #CNS Delivery: Showcasing our lead Amyotrophic Lateral Sclerosis (ALS) program, #MAPT program in Alzheimer's, and #SNCA program in Parkinson's disease. 🧬 SC-Formulated RNAi #MALFD Delivery: This highlights exciting news in our obesity program, which generated significant outcomes targeting the #INHBE gene. These results compare head-to-head against commercially available GLP1 programs. ⏳ 18-Week Durability Outcomes: Revolutionary results in epilepsy management through our novel IV-formulated RNAi delivery platform. Explore the intricacies of our RNAi delivery platform, designed to enhance stability, safety, and targeted delivery efficacy of diverse RNAi cargos (e.g., ASO, siRNA, and mRNA). Join us to delve into cutting-edge CNS and metabolic disease therapeutics and discuss the transformative potential of RNAi technology. 📧 Contact: [email protected] AbbVie, Christian R. Schubert, Avidity Biosciences, Inc., Alnylam Pharmaceuticals, Arbor Biotechnologies, Arrowhead Pharmaceuticals, AstraZeneca, BioMarin Pharmaceutical Inc., Fanny Cavalie, Dicerna Pharmaceuticals, Inc., Deep Genomics, Eli Lilly and Company, Christine Donahue, GSK, Horizon, Ionis Pharmaceuticals, Inc., Bayer | Pharmaceuticals, Christian Rommel, The Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis Gene Therapies, Novartis, Novo Nordisk, Jacob Petersen, ONO PHARMACEUTICAL CO., LTD., Otsuka Pharmaceutical Co., Ltd., Pedro Morais, Pfizer, #pfizercolleague, Benjamin Yaden, Regeneron, RNA Therapeutics and Oligonucleotides, Roche, Sanofi, Silence Therapeutics plc, Spark Therapeutics, Inc., Wave Life Sciences, NYSE. Nomura Securities International, Inc., Leerink Swann & Company #RNAi #CNS #ALS #Parkinsons #Alzheimers #Obesity #Epilepsy.  Learn more: https://lnkd.in/gD5rKNHq Fierce Life Sciences Events

16

#LNP for extrahepatic delivery is challenging. This paper from Dr. Robert (Bob) Prud'homme's lab explores the substitution of PEG lipid with biodegradable block copolymers (BCPs), specifically poly(ε-caprolactone)-block-poly(ethylene glycol) (PCL-b-PEG). BCPs offer strong anchoring for large macromolecules, potentially enhancing cell-specific targeting.   They found BCP-LNPs exhibit higher transfection efficiency in Hela cells and the targeted BCP-LNPs using a Cetuximab-conjugated formulation show significant promise in delivering cargo specific to EGFR-overexpressing cells (A549 cells), with up to 2.4 times higher transfection compared to nontargeted LNPs.  

44

2 Comments

High Cost of Laboratory Space Preventing Expansion? At Colorado Health & Tech Centers (CHTC), we offer solutions. With partially equipped laboratories to streamline lab set up and flexible terms, CHTC is prepared to support the growing life sciences and biotech ecosystem. Don’t let the high cost of setting up a lab hinder your innovation. Join the myriad of entrepreneurs who have experienced the benefits of competitively priced, world-class laboratory and office space. https://coloradohtc.com/ #Denverrealestate, #biotechnology, #Pharmaceutical, #biotech, #pharma, #innovation, #tech, #Technology, #CBSA, #CoBioscience, #cro , #cdmo, #laboratory,  #relocationspecialist, #Medicaldevice, #entrepreneurship, #startups, CO Hub for Health Impact, Newmark Colorado, Newmark, JLL, Cushman & Wakefield, Colorado BioScience Association, Colorado BioScience Institute , University of Colorado Anschutz Medical Campus, Denver Metro Chamber of Commerce, South Metro Denver Chamber

25

1 Comment